880 related articles for article (PubMed ID: 24075889)
21. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
[TBL] [Abstract][Full Text] [Related]
22. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
23. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
Pohl D; Fried M; Lawrance D; Beck E; Hammer HF
BMJ Open; 2019 Dec; 9(12):e025627. PubMed ID: 31892640
[TBL] [Abstract][Full Text] [Related]
24. Linaclotide for constipation-predominant IBS.
Drug Ther Bull; 2013 Nov; 51(11):129-32. PubMed ID: 24227771
[TBL] [Abstract][Full Text] [Related]
25. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
26. The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.
Chang L; Lembo AJ; Lavins BJ; Shiff SJ; Hao X; Chickering JG; Jia XD; Currie MG; Kurtz CB; Johnston JM
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1302-12. PubMed ID: 25312449
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
28. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
Rothstein RD; Friedenberg FK
Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
[TBL] [Abstract][Full Text] [Related]
29. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.
Atluri DK; Chandar AK; Bharucha AE; Falck-Ytter Y
Neurogastroenterol Motil; 2014 Apr; 26(4):499-509. PubMed ID: 24351035
[TBL] [Abstract][Full Text] [Related]
30. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
Love BL; Johnson A; Smith LS
Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
[TBL] [Abstract][Full Text] [Related]
31. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
Layer P; Stanghellini V
Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
[TBL] [Abstract][Full Text] [Related]
32. Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation.
Chey WD; Sayuk GS; Bartolini W; Reasner DS; Fox SM; Bochenek W; Boinpally R; Shea E; Tripp K; Borgstein N
Am J Gastroenterol; 2021 Feb; 116(2):354-361. PubMed ID: 33065589
[TBL] [Abstract][Full Text] [Related]
33. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
McCormack PL
Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
Drossman DA; Chey WD; Johanson JF; Fass R; Scott C; Panas R; Ueno R
Aliment Pharmacol Ther; 2009 Feb; 29(3):329-41. PubMed ID: 19006537
[TBL] [Abstract][Full Text] [Related]
35. Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.
Rey E; Mearin F; Alcedo J; Ciriza C; Delgado-Aros S; Freitas T; Mascarenhas M; Mínguez M; Santos J; Serra J
Adv Ther; 2017 Mar; 34(3):587-598. PubMed ID: 28083815
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
Shah ED; Kim HM; Schoenfeld P
Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
[TBL] [Abstract][Full Text] [Related]
37. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
[TBL] [Abstract][Full Text] [Related]
39. Pilot study on the effect of linaclotide in patients with chronic constipation.
Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
[TBL] [Abstract][Full Text] [Related]
40. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
Vazquez-Roque MI; Bouras EP
Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
